Andrew R. Kompa
Melbourne, VIC 3065, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Device encapsulated MSCs for adaptive secretome therapy to effectively target ischaemic heart injury.
Journal: Stem cell research & therapy
Published: June 22, 2025
An optimized plasmalogen modulating dietary supplement provides greater protection in a male than female mouse model of dilated cardiomyopathy.
Journal: Journal of molecular and cellular cardiology plus
Published: November 21, 2024
Rat Models of Cardiorenal Syndrome and Methods for Functional Assessment.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: April 27, 2024
Targeting G protein-coupled receptors for heart failure treatment.
Journal: British journal of pharmacology
Published: October 26, 2022
NP202 treatment improves left ventricular systolic function and attenuates pathological remodelling following chronic myocardial infarction.
Journal: Life sciences
Published: October 11, 2021
Sphingolipid imbalance and inflammatory effects induced by uremic toxins in heart and kidney cells are reversed by dihydroceramide desaturase 1 inhibition.
Journal: Toxicology letters
Published: March 18, 2021
RE: Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis.
Journal: International journal of cardiology
Published: September 16, 2020
RE: Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome.
Journal: International journal of cardiology
Published: August 10, 2020
The Preventable Productivity Burden of Kidney Disease in Australia.
Journal: Journal of the American Society of Nephrology : JASN
Published: August 08, 2020
The effect of dihydroceramide desaturase 1 inhibition on endothelial impairment induced by indoxyl sulfate.
Journal: Vascular pharmacology
Published: July 28, 2020
Last Updated: 09/26/2026